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Objectives. Our goals were to examine late clinical outcome in 
a cohort of patients who electively received Palmaz-Schatz intra- 
coronary stents, to identify specific predictors of outcome and to 
determine the time course of the development of ischemic ardiac 
events after stenting. 
Background. Short-term results of Palmaz-Schatz intracoro- 
nary stenting have been promising, with a reduction in both 
angiographic restenosis and clinical cardiac events up to 1 year 
after stenting. 
Methods. We analyzed the clinical outcomes in 65 consecutive 
patients who underwent stenting at least 3 years before analysis. 
Demographic, linical and procedural predictors of survival and 
event-free survival, defined as freedom from myocardial infarc- 
tion, stent-site percutaneous transluminal coronary angioplasty, 
coronary artery bypass graft surgery or death, were analyzed at a 
mean follow-up of 39 -+ 17 months. 
Results. Absolute survival and event-free survival at 3 years 
were 88% and 56%, respectively. Three-year f eedom from stent- 
site revascularization was 66%. Predictors of decreased long-term 
survival (p < 0.05) included diabetes and a high angina score 
(Canadian Cardiovascular Society class III/IV) at 6 and 12 
months after stenting. Predictors of decreased event-free survival 
(p < 0.05) included a high angina score at 3, 6 and 12 mouths 
after stenting, smaller stent deployment balloon size and greater 
number of stents implanted. Freedom from adverse vents by 6 
months after stenting also correlated with long-term event.free 
survival. Eighty-five percent of stent-site revascularizations oc- 
curred within 1 year. During late follow-up (>24 months), no 
patients had stent-site stenoses requiring revascularization, 
whereas 11% of patients required revascularization in nonstented 
coronary segments. 
Conclusions. Clinical predictors of worse long-term outcome 
included diabetes mellitus, higher angina score at follow.up, 
smaller stent deployment balloon size and greater number of 
stents at implantation. During follow-up, the majority of adverse 
events and stent-site revascularizations occurred early after stent- 
ing, and disease progression i  nonstented vessels accounted for 
the majority of late revascularization events. 
(JAm Coil Cardiol 1996;27:1185-91) 
Percutaneous transluminal coronary angioplasty is effective in 
the management of symptomatic coronary artery disease, but 
restenosis atthe angioplasty site remains amajor obstacle to its 
long-term success. Numerous pharmacologic nterventions 
have failed to alter significantly the natural course of resteno- 
sis. Intracoronary stents offer an alternative method for main- 
taining vessel patency, theoretically by reducing elastic recoil 
(1), by sealing intimal flaps, and by serving as a scaffold for the 
vascular wall, allowing greater vessel expansion. Early studies 
with the Palmaz-Schatz stent have documented a high success 
rate for stent delivery, both in native coronary arteries (2) and 
in saphenous vein grafts (3), with its only serious limitations 
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being subacute thrombosis (4) and a higher incidence of 
vascular access complications. 
Short-term results of Palmaz-Schatz intracoronary stenting 
have been promising, demonstrating a modest reduction in 
both angiographic restenosis and clinical cardiac events. In the 
multicenter Stent Restenosis Study (STRESS) (5), anglo- 
graphic restenosis at 6 months after intervention was 32% in 
the stent group compared with 42% in the angioplasty group. 
The Benestent trial (6) showed a similar angiographic benefit 
from stenting, with a 6-month restenosis rate of 22% in the 
stent group versus 32% in the angioplasty group. Both of these 
studies also demonstrated a reduction in the early rate of 
clinical cardiac events with stenting: 18% reduction in the 
STRESS trial and 32% in the Benestent trial. The 1-year 
follow-up of patients in the Benestent trial is also promising, 
with a persistent angiographic and clinical benefit (7). In 
another series (8), 80% of patients who electively received 
Palmaz-Schatz stents were free from death, myocardial infarc- 
tion and revascularization at 1 year after stenting. 
The long-term clinical follow-up of intracoronary stenting is
less well described. In the analysis by Carrozza et al. (9), 154 of 
220 (70%) successfully stented patients were free from death, 
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myocardial infarction and revascularization at 36 months. We 
report here the long-term clinical outcome of patients who 
underwent elective intracoronary stent placement at least 3 
years before this analysis. Our goals were to examine the late 
clinical outcome in this cohort, to identify specific predictors of 
outcome and to determine the time course of the development 
of ischemic cardiac events after stenting. 
Methods  
Study patients. Records of 65 consecutive patients who 
electively received intracoronary stents at the Hospital of the 
University of Pennsylvania between December 1988 and No- 
vember 1990 were analyzed. Patients whose stents were placed 
emergently or within 24 hours of antecedent balloon angio- 
plasty were excluded. Baseline characteristics, including pa- 
tient age, gender, cardiovascular risk factors, stenosis length, 
stent location, mean vessel diameter, balloon size, number of 
stents per patient and angina score, were analyzed to deter- 
mine which of these predicted long-term clinical success. We 
analyzed cardiovascular risk factors such as hypertension, 
diabetes, tobacco use, hypercholesterolemia andfamily history 
of coronary artery disease. Follow-up variables included inter- 
val angina, myocardial infarction, death, scintigraphy data, 
angiographic data and any subsequent revascularization pro- 
cedures. Clinical follow-up of patients was conducted at 1, 3, 6, 
12 and 24 months after stenting and at the time of this analysis. 
Analysis of all angiograms to assess vessel characteristics was 
performed by an experienced angiographer, and vessel size and 
stenosis length were determined using digital calipers (10,11). 
Indications for stenting. The majority of patients under- 
went intracoronary stenting because of restenosis at a prior 
angioplasty site. Other indications for stenting included com- 
plex lesions, such as eccentric or long stenoses or stenoses at 
tortuous sites, and routine lesions. Stents in both native 
coronary arteries and saphenous vein grafts were included in 
this analysis. 
Stent placement. Stent implantation was performed using 
the balloon-expandable Palmaz-Schatz coronary stent (John- 
son & Johnson Interventional Systems) according to standard 
protocol. Because these procedures were performed before the 
availability of the sheathed stent delivery system, most implan- 
tation procedures were performed using unsheathed stents 
hand-crimped by the operator onto a standard angioplasty 
balloon. The average inflation pressure was 9.9 atm, with only 
16% of patients undergoing high pressure balloon inflation 
(defined as inflation pressure ->11 atm). All patients received 
an anticoagulation regimen of 325 mg of aspirin daily and 
75 mg of dipyridamole three times a day before the procedure, 
and 10% low molecular weight dextran was infused at the time 
of stent implantation. The majority of patients were discharged 
on aspirin, dipyridamole and warfarin; subcutaneous heparin 
was administered to a minority of patients after discharge. 
Fonow.up. Initial assessment of angiographic success and 
in-hospital adverse vents was made before discharge. Patients 
were then contacted at 1, 3, 6, 12 and 24 months after stenting. 
Most patients (85%) had coronary angiography at 3 to 6 
months after stenting. Telephone interviews of patients who 
were available at the time of this analysis were conducted 
between 41 and 64 months after stenting (mean 51 months). At 
each follow-up visit, patients were assigned an angina score 
and interval myocardial infarction and death were recorded. 
Additionally, some patients underwent noninvasive scinti- 
graphic testing and were considered for coronary angiography 
as clinically indicated. 
Angina score. Patients were assigned an angina score to 
reflect the severity of their angina using the standard Canadian 
Cardiovascular Society system (12). For purposes of analysis, 
patients were assigned an angina score of 1 if their severity of 
angina at the time of stenting was not known. At follow-up, 
however, patients reporting no angina were assigned ascore of 0. 
Assessment of ischemia. Patients were classified as having 
recurrent ischemia ttributable to failure at the stent site if a 
seintigraphic ischemic perfusion defect in the stented vessel's 
distribution was present on either exercise or pharmacologic 
stress testing, or if--in the absence of scintigraphie data-- 
angina associated with electrocardiographic changes devel- 
oped during stress testing. 
Assessment of stent patency. Greater than 50% diameter 
stenosis at the stent site on follow-up angiography at any time 
after implantation constituted stent restenosis. 
End points. The two end points of the analysis were death 
and a composite clinical end point consisting of death, myo- 
cardial infarction or recurrent ischemia in the stented vessel 
distribution resulting in target vessel revascularization. Pa- 
tients with angina or ischemia not associated with angiographic 
restenosis at the stent site, or with asymptomatic angiographic 
restenosis not resulting in revascularization, did not achieve 
the composite clinical end point. 
Statistical analysis. The Fisher exact test was used to 
analyze the effects of dichotomous variables, and the two-tailed 
t test was used to analyze the effects of continuous variables in 
a univariate analysis. Statistical significance was determined 
when the null hypothesis was rejected at a confidence interval 
of 95%. Life tables were constructed using conventional sta- 
tistical software. 
Resul ts  
Patient characteristics. The clinical characteristics of the 
patient group and the angiographic haracteristics of the 
treated lesions are shown in Tables 1 and 2, respectively. 
Intracoronary stents were successfully implanted in 63 of 65 
patients (97%). Nineteen patients (29%) underwent coronary 
artery bypass graft surgery before stenting, and 42 patients 
(65%) underwent prior percutaneous transluminal coronary 
angioplasty. Restenosis after coronary angioplasty was the 
indication for 52% of stent implantations. 
Among the 65 patients, attempts were made to stent 72 
discrete lesions; 83 stents were successfully implanted in these 
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Table 1. Clinical Characteristics 
Age (yr) 59 _+ 9 
Male gender 75% 
Hypertension 55% 
Diabetes 28% 
Tobacco use 60% 
Cholesterol >200 mg/dl 55% 
CCS III/IV 57% 
Prior CABG 29% 
Prior MI 43% 
Data presented are mean value _+ SD or percent of patients. CABG = 
coronary artery bypass graft surgery; CCS = Canadian Cardiovascular Society 
angina class; MI = myocardial infarction. 
patients, with some lesions requiring more than one stent. 
Fifty-three (84%) of the successfully treated lesions were in 
native coronary arteries, whereas 10 (16%) were in vein grafts. 
Average vessel diameter was 3.3 _+ 0.5 mm and average lesion 
length was 9.8 _ 5.3 ram. 
Adverse events occurring after stent implantation but be- 
fore discharge included six vascular access ite complications 
(9%), three cases of bleeding (unrelated to access) requiring 
transfusion (5%) and two cases of stent hrombosis (3%). The 
stent thromboses were treated with emergent direct angio- 
plasty and did not result in Q-wave myocardial infarction. No 
Q-wave infarctions, coronary artery bypass operations or 
deaths occurred before discharge. 
Frequency and timing of end points. Table 3 outlines the 
clinical outcomes at each follow-up interval. The number of 
patients available at each follow-up are also shown in Table 3. 
In the early follow-up period after hospitalization (0 to 6 
months), major adverse vents included three deaths and one 
myocardial infarction. Only one death was attributable to 
failure at the stent site. One-quarter ofthe patients developed 
recurrent angina, with a median angina score of 2.5. Thirteen 
patients (24%) had restenosis at the stent site, requiring 
coronary angioplasty (10 patients) or bypass surgery (3 pa- 
tients). Asymptomatic angiographic restenosis was noted in 
seven patients, two of whom underwent coronary angioplasty. 
Between 6 and 12 months, major interval adverse vents 
included one death and two myocardial infarctions, all attrib- 
utable to stent failure. A substantial proportion of patients 
Table 2. Lesion Characteristics 
Restenotic lesion 52% 
Lesion location 
LAD 35% 
LCx 8% 
RCA 42% 
SVG 15% 
Vessel diameter (mm) 3.3 _+ 0.5 
Lesion length (ram) 9.8 -+ 5.3 
Data presented are mean value _+ SD or percent of patients. LAD - left 
anterior descending artery; LCx = left circumflex artery; RCA = right coronary 
artery; SVG = saphenous vein graft. 
Table 3. Stent-Site Failure and Clinical Outcomes 
Time at Follow-Up (mo) 
1 3 6 12 24 51' 
Pts available for 61 (97) 61 (97) 51 (85) 53 (89) 44 (77) 35 (63) 
follow-up 
Angina (interval) 5 (8) 15(24) 12(25) 11 (21) 10(23) 8(22) 
Positive stress test 3 (5) 7 (11) 2 (4) 4 (8) 2 (4) 1 (3) 
(interval) 
All death 0 0 3 (6) 1 (2) 2 (5) 1 (3) 
Stent-related death 
Interval 0 0 l (2) 1 (2) 1 (2) 0 
Cumulative 0 0 1 (2) 2 (4) 3 (8) 3 (8) 
All MI 0 0 1 (2) 2 (4) 1 (2) 0 
Stent-related MI
Interval 0 0 0 2 (4) 0 0 
Cumulative 0 0 0 2 (4) 2 (4) 2 (4) 
Stent PTCA 
Interval 0 5 (8) 5 (10) 3 (6)t 1 (2)t 0 
Cumulative 0 5 (8) 10(18) 13 (24) 14 (26) 14(26) 
CABG 
Interval 0 1 (2) 2 (4) 1 (2) 2 (5) 0 
Cumulative 0 1 (2) 3 (6) 4 (8) 6 (13) 6 (13) 
*Mean late follow-up, tSecond stent-site angioplasty in one patient of each 
group. Data presented are number (%) of patients. PTCA = percutaneous 
transluminal coronary angioplasty; Pts = patients; other abbreviations a in 
Table i. 
remained angina free (79%), and few patients howed isch- 
emia by noninvasive t sting (8%). Median angina score was 1. 
In all, four patients (8%) developed restenosis requiring 
revascularization, with three patients (6%) undergoing coro- 
nary angioplasty, and one patient (2%) undergoing bypass 
surgery. For one patient who required revascularization, this 
was the second coronary angioplasty after stenting. 
Between 12 and 24 months after stenting, major adverse 
events included two deaths and one myocardial infarction; only 
one of the deaths was attributable to stent failure. Median 
angina score was 2. Three patients (7%) required revascular- 
ization, yet only one patient had evidence of new stent 
restenosis. Of the two patients who underwent bypass urgery, 
one had an angiographically patent stent and the other had five 
stents originally placed in the culprit vessel, two of which were 
stenotic at this time. The patient who required angioplasty also 
underwent coronary angioplasty for stent restenosis at 3 
months. 
At the latest follow-up (mean 51 months), only one death 
occurred, and it was not attributed to stent failure. The 
majority of patients were free from angina, although a number 
of patients continued to have mild angina (median angina 
score 1). Between 24 months and the latest follow-up (mean 51 
months), none of these patients had restenosis in the stent 
distribution requiring revascularization. 
Absolute survival and event-free survival. Complete follow- 
up to 5 years was achieved in 10 patients, with a mean 
follow-up of 39 months among all patients. The absolute 
survival and event-free survival curves are shown in Figure 1. 
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From these curves, calculated 3-year survival was 88%, and 
3-year event-free survival was 56%. The majority of clinical 
cardiac events occurred early after stenting, with 35% of 
patients uffering an adverse event in the first 12 months. 
Thereafter, the incidence of adverse vents fell dramatically. 
Only one additional adverse vent, death not attributable to 
stent failure, occurred more than 24 months after stenting. 
Freedom from stent-site revascularization. Figure 2 dem- 
onstrates the occurrence of stent-site revascularization due to 
stent distribution ischemia. The majority of revascularizations 
at the stent site were performed early, with 85% of all stent-site 
revascularizations completed by 12 months. Three-year f ee- 
dom from stent-site revascularization was 66%. Of the patients 
who required stent-site revascularization, two patients (12%) 
ultimately required asecond intervention because of restenosis 
after coronary angioplasty. 
Long-term stability of the stent site. Thirty-four percent of 
patients had clinically significant restenosis at the stent site 
requiring revascularization. Seventy-six percent of these (13 
patients) presented within 6 months and 18% (3 patients) 
presented between 6 and 12 months after stenting. After 12 
months, only one patient (6%) who had been free of restenosis 
at 12 months ubsequently developed stenosis. No sites devel- 
oped restenosis after 24 months. 
Predictors of mortality and reduced event-free survival. 
The following variables were associated with higher mortality 
during the follow-up period in a univariate analysis (Table 
4)--a history of diabetes mellitus (p = 0.04) and a high angina 
score at 6 (p = 0.02) and 12 (p = 0.002) months after stent 
implantation. Of 18 diabetic patients who received stents, 72% 
were alive at follow-up, compared with 98% of nondiabetic 
patients. The following variables were associated with achieve- 
ment of the composite end point, representing decreased 
event-flee survival, during the follow-up period--high angina 
score at each follow-up interval (p < 0.002), greater number of 
stents at the primary lesion (p < 0.0001) and smaller balloon 
size (p = 0.02). Those patients who achieved the composite 
end point had an average of 1.4 _+ 0.9 stents implanted each 
and a mean balloon size of 3.1 + 0.2 ram. Those who did not 
achieve the composite nd point had an average of 1.2 + 0.4 
stents implanted each and a mean balloon size of 3.2 +_ 
0.3 mm. 
Figure 1. Life-table stimates of absolute survival (solid line) and 
event-free survival (dotted line) after stenting. Absolute 3-year survival 
was 88%; 3-year event-free survival was 56%. 
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Late clinical outcome also correlated with the occurrence of 
early adverse vents, with a trend toward statistical significance 
(p = 0.07), as shown in Figure 3. In this particular analysis, 
only 59 patients were included; the four patients who had died 
before the 6-month follow-up were excluded because their 
long-term clinical outcome could not be assessed. Patients who 
were free from death, myocardial infarction, stent restenosis or 
revascularization at 6 months (group I, n = 43) had a 16% 
frequency of subsequent adverse vents. In contrast, patients 
who already experienced an adverse vent in the first 6 months 
(group II, n = 16) had a 44% frequency of subsequent adverse 
events during long-term follow-up. 
Progression of coronary artery disease. Although stent 
patency was preserved among the majority of patients during 
long-term follow-up, progressive atherosclerosis in nonstented 
coronary segments became more prevalent. We defined new 
coronary stenosis as any 50% diameter stenosis outside the 
stented segment discovered at angiographic follow-up. Of all 
new coronary stenoses, the majority (79%) were detected in 
vessels other than the stented vessel. Figure 4 demonstrates he 
incidence of new coronary stenoses during follow-up and their 
relative importance in late revascularization. As shown in 
Figure 4A, the incidence of new coronary stenoses in non- 
stented segments increased ramatically after 6 months, and 
coronary angioplasty was performed in approximately half of 
all new lesions at each follow-up interval. At 24 months after 
stenting, angiographically significant stenoses outside the stent 
site were detected in 23% of patients. Figure 4B shows the 
relative frequencies ofrevascularization at long-term follow-up 
in stented versus nonstented segments. Between 12 and 39 
months, 25% of patients required revascularization at sites 
other than the stent site, whereas only one patient (5%) 
required stcnt-site revascularization. 
Discuss ion  
In this study, the clinical and angiographic outcomes in 65 
consecutive patients who underwent elective Palmaz-Schatz 
intracoronary stent implantation were analyzed at a mean 
follow-up of 39 _+ 17 months. Recently, two large prospective 
trials demonstrated the effectiveness of Palmaz-Schatz stents in 
reducing short-term angiographic restenosis and clinical car- 
diac events. Long-term clinical outcome after this procedure 
still requires further study. Our single-center experience is 
presented here. 
Long-term clinical outcome. We found that 88% of pa- 
tients who received stents uccessfully were alive at a follow-up 
interval of 3 years. Three-year event-free survival was 56%. 
Three-year f eedom from stent-site revascularization was 66%. 
These findings are particularly remarkable, considering that 
the stented lesion characteristics would predict a large fre- 
quency of restenosis (52% prior restenosis, 10% saphenous 
vein grafts, mean lesion length 9.8 +_ 5.3 ram). Clinical 
assessment a each follow-up interval revealed good functional 
capacity, with most patients free of angina t any given point in 
time, and a maximal mean angina score (among symptomatic 
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Figure 2. Freedom from stent-site revascularization during follow-up. 
Three-year f eedom from revascularization was 66%. Eighty-five per- 
cent of all stent-site revascularizations were performed by 12 months. 
patients) of 2.6 at 6 months. The vast majority of adverse 
clinical events and revascularization procedures attributable to 
stent failure occurred within the first 12 months after stenting. 
Specifically, the need for stent-site revascularization was great- 
est within the first 6 months (24%). Only 9% of patients 
developed clinically significant stent restenosis after 6 months; 
only 2% (one patient) required target lesion revascularization 
after 1 year. These results demonstrate long-term stability at 
the stent site. 
Progression of coronary artery disease. Although the need 
for stent-site revascularization decreased markedly after the 
first several months, many patients developed symptomatic 
atherosclerosis in other vascular territories. Thus, in contrast 
to the predominance of stent-site revascularizations during 
short-term follow-up, revascularization i nonstented seg- 
ments predominated uring late follow-up. This finding has 
also been noted among patients undergoing conventional 
angioplasty (13), and likely reflects the progressive nature of 
coronary artery disease. 
Clinical predictors of outcome. The two most useful pre- 
dictors of outcome in this analysis are the severity of angina at 
Table 4. Predictors of Absolute Survival and Event-Free Survival 
Absolute Survival Event-Free Survival 
Variable (p value) (p value) 
Baseline angina score 0.38 0.40 
Angina score 
3 mo 0.14 0.002* 
6 mo 0.02* < 0.0001' 
12 mo 0.002* < 0.0001' 
Age 0.40 0.92 
Diabetes inellitus 0.04"~ 0.13 
Family history 1.00 0.44 
Gender 0.18 0.35 
Tobacco use 1.00 0.99 
Hypercholesterolemia 0.23 0.94 
Hypertension 0.72 0.65 
Stent location 0.51 0.66 
Balloon size 0.83 0.02* 
Stenosis length 0.09 0.56 
No. of stents 0.06 < 0.0001" 
*Two-tailed t test. ~Fisher exact test. 
50 
4O 
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20 
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Figure 3. Occurrence of adverse events more than 6 months after 
stenting in two groups of patients. Patients who had not experienced an 
adverse vent in the first 6 months (group I, n = 43) had a lower 
frequency of subsequent adverse vents than those patients who had 
experienced an early event (group II, n = 16). CABG = coronary 
artery bypass graft surgery; MI = myocardial infarction; PTCA = 
percutaneous transluminal coronary angioplasty. 
each follow-up interval and the occurrence of adverse vents 
before the 6-month follow-up. Both of these clinical measures 
are easily assessed and identify subsets of patients at subse- 
quently higher risk for death, myocardial infarction or the need 
for revascularization. Patients who do not have recurrent 
angina or experience an adverse outcome in the first 6 months 
after stent placement appear to have a better long-term 
prognosis. 
Among the demographic variables tested in this analysis, 
including age, gender, cardiovascular risk factors and history of 
prior intervention, only the presence of diabetes mellitus 
predicted decreased absolute survival. It has been demon- 
strated previously that diabetic patients are at increased risk 
for restenosis after intracoronary stenting (14). Patients with 
diabetes are also predisposed to cerebrovascular nd periph- 
eral vascular disease, renal failure and infection, which may 
have influenced their mortality risk in this analysis. 
Other potentially relevant demographic variables, such as 
vessel type (native coronary artery versus vein graft) and 
history of prior angioplasty in the stented vessel, were not 
Figure 4. Development of new coronary stenoses and the need for 
revascularization. A, The incidence of new coronary stenoses in 
nonstented segments increased substantially during long-term follow- 
up. B, Revascularization i  nonstented segments was more common 
than stent-site revascularization during late follow-up. Solid bars = 
nonstent segment; open bars = stent segment. 
A.  B°  
6 12 24 12 to 24 24 to 39 
Months Months 
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found to predict long-term outcome. In previous reports, 
stenting of either estenotic lesions (15) or lesions in vein grafts 
(16) correlated with an increased risk of stent restenosis or the 
need for subsequent revascularization. In this study, 4 of 10 
patients (40%) who underwent stenting of saphenous vein 
grafts ultimately required revascularization at the stent site, 
but the number of vein graft stents is too small to detect a 
statistically significant difference in outcome when compared 
with those stents in native coronary arteries. 
Both smaller balloon used for stent implantation and 
greater number of stents at implantation predicted ecreased 
event-free survival. Other investigators have reported a more 
favorable outcome with the use of a larger stent deployment 
balloon, which likely reflects the achievement of a greater 
immediate lumen diameter (17). Achievement of the largest 
possible acute lumen diameter may provide better tolerance of 
subsequent hyperplasia before hemodynamically significant 
restenosis occurs (18). Alternatively, as more recent evidence 
suggests, larger deployment balloon diameter may reduce 
immediate vascular ecoil in implanted stents (19). Regardless 
of the mechanism, our data demonstrate hat the larger lumen 
diameter achieved by the use of larger balloons after the 
procedure was associated with a reduction in adverse clinical 
events. 
Multiple stents at implantation also predicted ecreased 
event-free survival. This may be a result of either the additive 
risks that each individual stent imposes when placed in non- 
tandem fashion or the inherent lesion complexity which war- 
ranted tandem stent implantation. 
Study limitations. This study has certain important limita- 
tions. First, because the patients in this study received stents 
before widespread approval of intracoronary stents for routine 
use, many of them had advanced coronary artery disease and 
had undergone antecedent revascularization. Nearly one-third 
of patients had undergone prior coronary artery bypass, and 
almost two-thirds prior angioplasty. More than one-half of 
patients had undergone angioplasty in the vessel subjected to 
stent implantation. Outcomes and predictors may be different 
in a patient group without such selection bias. Second, because 
of the retrospective d sign of this study, follow-up could not be 
achieved for all patients at all follow-up intervals, which may 
affect outcome measurements. Third, because all-cause mor- 
tality was an end point criterion, some deaths not attributable 
to stent failure are included in the outcomes analysis. One 
patient died of complications of angioplasty in another vessel, 
and another patient died of lymphoma. In other cases it was 
not possible to determine the cause of death. An overestima- 
tion of long-term adverse sequellae of intracoronary stenting 
results from the inclusion of these events. Finally, these stent 
procedures were performed before widespread application of 
high pressure balloon inflation, which may ultimately improve 
long-term event-free survival, thereby affecting outcomes and 
predictors. 
Clinical implications. Despite the above limitations, this 
study provides auseful assessment of the long-term success of 
Palmaz-Schatz intracoronary stenting, in terms of both abso- 
lute survival and long-term event-free survival. We have dem- 
onstrated that the majority of adverse clinical events occur 
early after stent implantation, and that revascularization at the 
stent site primarily occurs within the first 12 months. During 
long-term follow-up, however, asubstantial number of patients 
develop symptomatic coronary artery disease in other vascular 
territories, reflecting the natural history of coronary artery 
disease. Late revascularization is therefore most commonly 
performed when disease has progressed to nonstented seg- 
ments. Clinical predictors of worse long-term clinical outcome 
include diabetes mellitus and higher angina score at follow-up. 
Experiencing an early adverse vent after stenting also por- 
tends a worse long-term prognosis. Finally, use of a single stent 
and the largest possible stent deployment balloon confers the 
greatest long-term clinical benefit. In the future, it will be 
important o determine whether the estimates of absolute 
survival and event-free survival derived from this study are 
applicable to patients who receive stents for "routine" stenotic 
lesions, and not for lesion complexity or restenosis, the two 
principal indications in this patient group. 
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